

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	. FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/708,239	(02/18/2004	William Douglas Cress JR.	1372.133.PRC 2238	
21901	7590	07/11/2005		EXAMINER	
	HOPEN F		VIVLEMORE, TRACY ANN		
15950 BA' SUITE 220	Y VISTA DI)	RIVE	ART UNIT	PAPER NUMBER	
CLEARW	ATER, FL	33760	1635		

DATE MAILED: 07/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		10/708,239	CRESS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Tracy Vivlemore	1635				
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover sheet with the	correspondence address				
THE I - Exter after - If the - If NO - Failu Any I	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR of SIX (6) MONTHS from the mailing date of this communication. To period for reply specified above is less than thirty (30) days, a restrict of the reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by staturely received by the Office later than three months after the mained patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a reply be eply within the statutory minimum of thirty (30) d id will apply and will expire SIX (6) MONTHS fro ute, cause the application to become ABANDON	timely filed ays will be considered timely, om the mailing date of this communication, NED (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on		·				
· •	This action is FINAL. 2b)⊠ This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
5)	Claim(s) 1-11 is/are pending in the application 4a) Of the above claim(s) is/are withden Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-11 are subject to restriction and/or	rawn from consideration.					
Applicat	ion Papers	•	•				
9)[The specification is objected to by the Exami	ner.	·				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the						
Priority (under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
Attachmen	ot(s) ce of References Cited (PTO-892)	4) 🔲 Interview Summa	ary (PTO-413)				
2) Notice 3) Infor	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 er No(s)/Mail Date	Paper No(s)/Mail					

Application/Control Number: 10/708,239 Page 2

Art Unit: 1635

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-5, drawn to a method of modulating apoptosis in a target cell population by regulating expression of E2F1, classified in class 514, subclass 44.
- II. Claims 6-11, drawn to a vector comprising a BS/Us E2F1 RNAi plasmid, classified in class 435, subclass 320.1.

The inventions are distinct, each from the other because of the following reasons:

- 1. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process could be performed with a materially different product, for example, apoptosis could be modulated by altering expression of IAP gene.
- 2. Furthermore, examining invention I together with invention II would impose a serious search burden. In the instant case, prior art searches of methods of inhibiting apoptosis by regulating E2F1 are not coextensive with prior art searches of vectors comprising a BS/U6 E2F1 RNAi plasmid; the method as claimed encompasses more

Art Unit: 1635

agents to regulate expression. Search of each of these inventions would require different key word searches of each compound and of each distinctive step of the method using divergent patent and non-patent literature databases. The different searches would then require subsequent in-depth analysis of the unrelated prior art literature, placing a serious burden on the Office in terms of both search and examination. As such, it would be burdensome to perform examination of inventions I and II together.

Page 3

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is

found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-2914. The examiner can normally be reached on Mon-Fri 8:45-5:15.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's acting supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file

Application/Control Number: 10/708,239

Art Unit: 1635

folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Tracy Vivlemore Examiner Art Unit 1635

TV July 6, 2005

JAMES SCHULTZ
PATENT EXAMINER

Page 6